Presentations highlight clinically meaningful reductions in BMI in patients with acquired hypothalamic obesity – - Full data ...

Rhythm Pharmaceuticals jumps 36.6% after its oral drug bivamelagon shows strong BMI and hunger reductions in a phase II study in acquired hypothalamic obesity.

Fintel reports that on July 7, 2025, Leerink Partners initiated coverage of Rhythm Pharmaceuticals (NasdaqGM:RYTM) with a ...

Rhythm Pharmaceuticals' potential first-in-class HO drug, strong pipeline, and limited competition offer blockbuster potential. Click to read why RYTM is a Buy.

Shares of Rhythm Pharmaceuticals RYTM were up 36.6% yesterday after it reported positive top-line data from a phase II study evaluating the investigational oral melanocortin-4 receptor (MC4R ...

We just received data on a new analyst forecast for $RYTM. Joseph Stringer from Needham set a price target of 95.0 for RYTM.

Rhythm Pharma (RYTM) stock gains as the company's experimental therapy bivamelagon shows promise in Phase 2 trial for rare acquired hypothalamic obesity. Read more here.

Rhythm's bivamelagon cut BMI and hunger scores in Phase 2 trial for hypothalamic obesity, prompting plans to discuss Phase 3 ...

Get today's Rhythm Pharma stock news. We cover the latest Rhythm Pharma headlines and breaking news impacting Rhythm Pharma stock performance.